Efficacy and Safety of Task-activated rTMS in Improving Cognitive Function in Patients With Bipolar Disorder

Prior treatment

• Those with neurological diseases or risk of epileptic seizures, such as previous craniocerebral diseases, head trauma, alcoholism, abnormal EEG, MRI evidence of abnormal brain structure, or a family history of epilepsy;
• Those with contraindications to MRI scanning or transcranial magnetic stimulation treatment, such as those with metal or electronic devices in the body (metal foreign bodies in the brain, cochlear implants, pacemakers and stents);

Other illness

• Those with a history of severe physical illness or diseases that may affect the central nervous system (such as tumors, syphilis, etc.);
• Those with color blindness or hearing impairment;
• Those with a history of substance or alcohol abuse;

Other

• Those at high risk of suicide, or those who have already committed suicide or serious self-harm and need emergency intervention;
• Those who are pregnant, breastfeeding, or planning to become pregnant during the trial;
• Other situations that the researcher determines are not suitable as research subjects.

• Aged 14 to 45 years, right-handed;
• Meet the diagnostic criteria for bipolar disorder in the stable remission period of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5);
• Stable medication treatment;
• Clinical remission for more than three months, Young Mania Rating Scale (YMRS) ≤ 6 points Hamilton Depression Rating Scale 17 (HDRS 17) score ≤ 7 points;
• Cognitive impairment on the Cognitive Deficit Questionnaire (PDQ) ≥ 17 points;
• Fully understand the transcranial magnetic stimulation treatment, be willing to actively cooperate with the treatment, and sign the informed consent.